Correction: Mahnashi et al. In-Vitro, In-Vivo, Molecular Docking and ADMET Studies of 2-Substituted 3,7-Dihydroxy-4H-chromen-4-one for Oxidative Stress, Inflammation and Alzheimer’s Disease. Metabolites 2022, 12, 1055

There was an error in the original publication [1]. The authors request to delete Reference [83] and replace the [83] “Xu, S.; Tao, H.; Cao, W.; Cao, L.; Lin, Y.; Zhao, S.-M.; Xu, W.; Cao, J.; Zhao, J.-Y. Ketogenic diets inhibit mitochondrial biogenesis and induce cardiac fibrosis. Signal Transduct. Target. Ther. 2021, 6, 54” with Reference [61] “Wang, D.; Zhao, R.; Qu, Y.-Y.; Mei, X.-Y.; Zhang, X.; Zhou, Q.; Li, Y.; Yang, S.-B.; Zuo, Z.-G.; Chen, Y.-M.; et al. Colonic Lysine Homocysteinylation Induced by High-Fat Diet Suppresses DNA Damage Repair. Cell Rep. 2018, 25, 398–412”.

A correction has been made to Section 4, Paragraph 6:

Free radicals are generated during metabolic processes in the body and are subsequently neutralized by natural antioxidant system like catalases and hydro-peroxidases [79,80]. However, in case of excessive free radical production or the body’s inability to scavenge the free radicals effectively, supplementation of exogenous antioxidants is extremely necessary [81]. In AD, Aβ proteins are deposited in the brain, which is considered as a mitochondrial poison. After production, it readily attacks lipids, membranes, proteins and nerve cells, causing genetic mutations, cells deterioration and the disruption of energy production by mitochondria [82]. Subsequently, supplementation of antioxidants is an integral part of the drug combinations for AD patients. Natural products and their derived compounds have received considerable attention as potential multi-target agents. Of particular interest is polyphenols which, being part of natural products and nutraceuticals, can delay the aging process and can act on multiple targets of AD. Numerous flavonoids are reported to inhibit cholinesterases, BACE1, scavenge free radicals and act as anti-inflammatory agents [61]. In the current study, our test compound showed efficacy on multiple targets and thus acts as a multi-target lead compound. However, further detailed studies regarding the bioavailability and in-vivo efficacy are required.

The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.